This protocol addresses the management of Dementia with Lewy bodies (DLB) presenting with depressive symptoms — a recognised and clinically relevant comorbidity in this condition.
Depressive symptoms occur frequently in patients with DLB. Despite this prevalence, robust trial data in this specific population remain scant, making careful, individualised clinical judgement essential when selecting an approach.
Management draws on a class of antidepressant agents, with selection guided by each patient's individual tolerability and clinical response. The full structured regimen — including sequencing, agent selection, and monitoring considerations — is available via the protocol.
DOI: 10.1212/WNL.0000000000004058
Although depressive symptoms are common in DLB, trial data are scant.
In alignment with general advice on depression in dementia, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and mirtazapine are options in DLB with treatment guided by individual patient tolerability and response.
View source ↗